Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
Oculis reported Q3 2026 results with $252.0 million in cash and short-term investments, providing runway into 2H 2029 as it advances two late-stage programs. Patient randomization is complete in the PREDICT-1 registrational trial of Licaminlimab in TNFR1-mediated dry eye disease (176 patients), with topline data expected around year-end 2026 — a potential first precision medicine in ophthalmology. Privosegtor's PIONEER-1 trial in optic neuritis is advancing, with IND clearance for acute MS relapses expected in Q4 2026 and new biomarker data supporting its neuroprotective potential.
Key figures
- Revenue
- 0
- Cash runway
- into 2H 2029
- Q3 loss chf
- CHF 18.2 million
- Net loss 9m chf
- CHF 57.1 million
- Net loss 9m usd
- 71700000
- Ga expense q3 usd
- 10600000
- Rd expense q3 usd
- 18500000
- Predict 1 enrollment
- 176
- Cash and investments chf
- CHF 210.3 million
- Cash and investments usd
- 252000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.